Summit Therapeutics jumps as ivonescimab catalysts near, including Q2 interim Phase III readout
Summit Therapeutics shares rose about 8.6% as investors refocused on ivonescimab’s near-term catalyst calendar, including planned HARMONi-3 squamous interim PFS analysis in Q2 2026. Recent disclosures also highlighted intracranial efficacy data from the Phase III HARMONi study and an FDA PDUFA goal date of November 14, 2026 for the ivonescimab BLA.
1. What’s driving the move
Summit Therapeutics (SMMT) is trading higher as the market reprices its lead asset, ivonescimab (SMT112/AK112), ahead of multiple 2026 clinical and regulatory milestones. The company has guided to an interim progression-free survival (PFS) analysis for the squamous cohort of its global Phase III HARMONi-3 study in Q2 2026, keeping the next potential datapoint close on the calendar. (s206.q4cdn.com)
2. The new data point investors are focusing on
Recent company disclosures emphasized ivonescimab’s intracranial activity in patients with and without baseline brain metastases in the global Phase III HARMONi study, a dataset that can matter for positioning in advanced NSCLC. In that update, ivonescimab plus chemotherapy showed longer intracranial PFS versus chemotherapy alone in both baseline brain-metastases and no-baseline-CNS-metastases subgroups. (smmttx.com)
3. Regulatory setup and key dates
Summit has stated that the FDA accepted its BLA for filing in January 2026 and set a PDUFA goal action date of November 14, 2026, providing a defined regulatory endpoint that can amplify sensitivity to interim clinical updates and investor-conference commentary in the run-up. (smmttx.com)
4. What to watch next
Near-term attention is on any incremental color around the Q2 2026 HARMONi-3 squamous interim PFS analysis (including timing and statistical details), plus additional ivonescimab datasets being featured around major lung-cancer scientific meetings. Separately, the stock may remain headline-driven as traders position for the November 2026 PDUFA decision, with volatility typical for single-asset, late-stage biotech stories.